**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 76-year-old man developed acute generalized exanthematous pustulosis (AGEP) during treatment with hydroxychloroquine (off-label), piperacillin/tazobactam and voriconazole. Additionally, the man received off-label treatment with azithromycin and ceftriaxone for COVID-19.

The man, presented to emergency department on 23 March 2020 for cough and diarrhea which had started since 17 March. Chest CT scan exhibited bilateral patchy ground glass opacities consistent with COVID-19, he was sent back home as no severity criteria were met. On 24 March, his symptoms aggravated with asthenia, fever and dyspnoea, and he was initiated on off-label treatment with oral hydroxychloroquine 200 mg/8h along with oral azithromycin 500 mg/day and IV ceftriaxone 1 g/day. On 29 March, his condition worsened with acute respiratory distress syndrome (ARDS), which required invasive mechanical ventilation, and was transferred to ICU.

On 25 March, azithromycin dose was decreased to 250 mg/24h and was discontinued on 28 March. Ceftriaxone and hydroxychloroquine were discontinued on 29 March after a cumulative dose of hydroxychloroquine of 3600mg. The SARS-Cov-2 real-time PCR test from the nasopharynx was positive. Bronchoscopy with bronchoalveolar lavage identified *Aspergillus fumigatus*and *Candida albicans*. COVID-19 improved with weaning of mechanical ventilation, and on 3 April the man, developed a pustular eruption on a background of edematous erythema of 2 days duration, which began on intertriginous areas (intergluteal, axillary, and inguinal) and rapidly affected 30% of body surface area. Fever was noted, laboratory investigations revealed an increased leucocytosis with marked neutrophilia. Hydroxychloroquine level was reported to be 325 µg/L. A skin biopsy revealed spongiform sub-corneal and intracorneal pustules, some keratinocyte necrosis, and a dermal inflammatory infiltrate of neutrophils with perivascular accentuation, confirming the diagnosis of AGEP with a RegiSCAR score of 11. The rash was already present on 1 April, the day IV voriconazole 600 mg/12h was started and 24 hours after the last dose of IV piperacillin/tazobactam 4 g/6h on 30 March, indicating that these were less suggestive of the culprit drug compared with hydroxychloroquine. On 13 April, 10 days after the AGEP diagnosis, he died due to massive pulmonary embolism.
